Medicine Overview of Tetrazin 12.5 12.5mg Tablet
Tetrazin 12.5 is a prescription medicine used to treat Huntington’s disease, a condition in which nerve cells in the brain breakdown over time, thus deteriorating the person’s physical and mental abilities. It also helps to relieve uncontrollable and jerky movements of the body.
Tetrazin 12.5 should be taken with or without food. However, it is advised to take it at the same time each day as this helps to maintain a consistent level of medicine in the body. Take this in the dose and duration as advised by your doctor and if you have missed a dose, take it as soon as you remember. It is important that this medication is not stopped suddenly without talking to your doctor as it may worsen your symptoms. However, discontinue this medicine immediately if you experience neuroleptic malignant syndrome, characterized by fever, muscle rigidity and altered consciousness or seizures.
Some common side effects of this medicine include nausea, insomnia(difficulty sleeping), anxiety, fatigue, akathisia (restlessness and inability to stay still) and depression. It also causes dizziness and sleepiness, so do not drive or do anything that requires mental focus until you know how this medicine affects you. Inform your doctor if you develop any unusual changes in mood or behavior, new or worsening depression, or suicidal thoughts while taking this medicine.
- Huntington's disease
- Nausea
- Insomnia (difficulty in sleeping)
- Anxiety
- Fatigue
- Sleepiness
- Akathisia (inability to stay still)
- Depression
-
You have been prescribed Tetrazin 12.5 to help control movement disorders such as in Huntington’s disease.
-
Be cautious while driving or doing anything that requires concentration as Tetrazin 12.5 can cause dizziness and sleepiness.
-
Inform your doctor if you experience symptoms such as high fever, sweating, muscle stiffness, and faster breathing. These may be due to a rare side effect known as the neuroleptic malignant syndrome.
-
Inform your doctor if you develop any unusual changes in mood or behavior, new or worsening depression, or suicidal thoughts or behavior.
-
Do not stop taking Tetrazin 12.5 without talking to your doctor first as it may cause worsening of symptoms.
Oral
Huntington Disease
Indicated for treatment of chorea associated with Huntington’s disease
Adult:
Individualize and slowly titrate dosage over several weeks to identify a dose that reduces chorea and is well tolerated
Total daily dose up to 50 mg/day
12.5 mg PO qDay initially; after 1 week, the dose should be increased to 12.5 mg q12hr
Maintenance: Titrate slowly by weekly intervals of 12.5 mg/day to identify dose that reduces chorea and is tolerated
If daily dose is 37.5 to 50 mg/day, administer in divided doses q8hr
Elderly: Initially 12.5 mg daily, increased gradually.
Total Daily dose >50 mg/day
If >50 mg/day is required, test and genotype to determine if poor or extensive metabolizers of CYP2D6; not to exceed 100 mg/day or 37.5 mg/dose
Moderate to severe tardive dyskinesia
Adult: Initially 12.5 mg daily increased gradually according to response.
Hepatic impairment
Contraindicated; it is not possible to adjust the dose to ensure safe use
Reversibly inhibits human vesicular monoamine transporter type 2 (VMAT2), resulting in decreased uptake of monoamines (eg, dopamine, serotonin, norepinephrine, histamine) into synaptic vesicles and depletion of monoamine stores from nerve terminals
This effect is similar to reserpine, but with less peripheral activity and is shorter-acting
>10%
Sedation/somnolence (31%),Fatigue (22%),Insomnia (22%),Depression (19%),Akathisia (19%),Extrapyramidal event (15%),Anxiety (15%),Nausea (13%)
1-10%
Irritability (9%),Bruising (6%),Vomiting (6%),Decreased appetite (4%),Dysuria (4%),Obsessive reaction (4%),Imbalance (9%),Parkinsonism/bradykinesia (9%),Dizziness (4%),Dysarthria (4%),Unsteady gait (4%),Headache (4%)
Frequency Not Defined
QTc prolongation,Neuroleptic malignant syndrome,Orthostatic Hypotension,Restlessness and agitation,Dysphagia,Depression and suicidality
Potentially Fatal: Neuroleptic malignant syndrome (NMS).
Pregnancy
There are no adequate data on the developmental risk associated with therapy in pregnant women; administration of tetrabenazine to rats throughout pregnancy and lactation resulted in an increase in stillbirths and postnatal offspring mortality
Lactation
There are no data on presence of tetrabenazine or metabolites in human milk, effects on breastfed infant, or on milk production; developmental and health benefits of breastfeeding should be considered along with mother’s clinical need for therapy and potential adverse effects on breastfed infant or underlying maternal condition
Reviews
Clear filtersThere are no reviews yet.